The studied parameters and endpoints in these clinical trials were AKI, GFR, conventional as well as novel biomarkers of kidney function (e.g., urine NGAL/urine Cr and KIM-1), and electrolytes imbalances. Here, LCN2 is linked to acute kidney injury.